These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 2883012)
21. A study of the mechanism of MDMA ('ecstasy')-induced neurotoxicity of 5-HT neurones using chlormethiazole, dizocilpine and other protective compounds. Colado MI; Green AR Br J Pharmacol; 1994 Jan; 111(1):131-6. PubMed ID: 7516800 [TBL] [Abstract][Full Text] [Related]
22. Oral administration of 3,4-methylenedioxymethamphetamine (MDMA) produces selective serotonergic depletion in the nonhuman primate. Ali SF; Newport GD; Scallet AC; Binienda Z; Ferguson SA; Bailey JR; Paule MG; Slikker W Neurotoxicol Teratol; 1993; 15(2):91-6. PubMed ID: 7685472 [TBL] [Abstract][Full Text] [Related]
23. Effect of flunarizine and nimodipine on the decrease in tryptophan hydroxylase activity induced by methamphetamine and 3,4-methylenedioxymethamphetamine. Johnson M; Mitros K; Stone DM; Zobrist R; Hanson GR; Gibb JW J Pharmacol Exp Ther; 1992 May; 261(2):586-91. PubMed ID: 1374469 [TBL] [Abstract][Full Text] [Related]
24. Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons. Schmidt CJ; Taylor VL Eur J Pharmacol; 1988 Oct; 156(1):121-31. PubMed ID: 2463176 [TBL] [Abstract][Full Text] [Related]
25. MDMA: historical perspectives. Gibb JW; Johnson M; Stone D; Hanson GR Ann N Y Acad Sci; 1990; 600():601-11; discussion 611-2. PubMed ID: 1979213 [No Abstract] [Full Text] [Related]
26. Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4-methylenedioxymethamphetamine, on central serotonergic and dopaminergic systems. Johnson M; Elayan I; Hanson GR; Foltz RL; Gibb JW; Lim HK J Pharmacol Exp Ther; 1992 May; 261(2):447-53. PubMed ID: 1349640 [TBL] [Abstract][Full Text] [Related]
28. Reserpine does not prevent 3,4-methylenedioxymethamphetamine-induced neurotoxicity in the rat. Hekmatpanah CR; McKenna DJ; Peroutka SJ Neurosci Lett; 1989 Sep; 104(1-2):178-82. PubMed ID: 2573011 [TBL] [Abstract][Full Text] [Related]
29. Regional distribution to recovery of 5-HT levels after administration of "atrophins" MDMA and D,L-fenfluramine. Stereospecificity and comparison with 5,7-dihydroxytryptamine. Lehmann J; DeSouza EB; Culp S; Zaczek R Ann N Y Acad Sci; 1992 May; 648():291-5. PubMed ID: 1379013 [No Abstract] [Full Text] [Related]
30. Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. Steele TD; Nichols DE; Yim GK Biochem Pharmacol; 1987 Jul; 36(14):2297-303. PubMed ID: 2886126 [TBL] [Abstract][Full Text] [Related]
31. Characterization of acute N-ethyl-3,4-methylenedioxyamphetamine (MDE) action on the central serotonergic system. Johnson M; Hanson GR; Gibb JW Biochem Pharmacol; 1989 Dec; 38(23):4333-8. PubMed ID: 2480796 [TBL] [Abstract][Full Text] [Related]
32. Effect of MK-801 on the decrease in tryptophan hydroxylase induced by methamphetamine and its methylenedioxy analog. Johnson M; Hanson GR; Gibb JW Eur J Pharmacol; 1989 Jun; 165(2-3):315-8. PubMed ID: 2570704 [TBL] [Abstract][Full Text] [Related]
33. Neurotoxic effects of the alpha-ethyl homologue of MDMA following subacute administration. Johnson MP; Nichols DE Pharmacol Biochem Behav; 1989 May; 33(1):105-8. PubMed ID: 2476831 [TBL] [Abstract][Full Text] [Related]
34. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Colado MI; Williams JL; Green AR Br J Pharmacol; 1995 Aug; 115(7):1281-9. PubMed ID: 7582557 [TBL] [Abstract][Full Text] [Related]